In last trading session, Intellia Therapeutics Inc (NASDAQ:NTLA) saw 5.91 million shares changing hands with its beta currently measuring 1.97. Company’s recent per share price level of $12.28 trading at $0.75 or 6.50% at ring of the bell on the day assigns it a market valuation of $1.25B. That closing price of NTLA’s stock is at a discount of -183.96% from its 52-week high price of $34.87 and is indicating a premium of 27.04% from its 52-week low price of $8.96.
For Intellia Therapeutics Inc (NTLA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.56. Splitting up the data highlights that, out of 13 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 13 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Intellia Therapeutics Inc (NASDAQ:NTLA) trade information
Upright in the green during last session for gaining 6.50%, in the last five days NTLA remained trading in the green while hitting it’s week-highest on Wednesday, 02/19/25 when the stock touched $12.28 price level, adding 4.06% to its value on the day. Intellia Therapeutics Inc’s shares saw a change of 5.32% in year-to-date performance and have moved 33.33% in past 5-day. Intellia Therapeutics Inc (NASDAQ:NTLA) showed a performance of 29.26% in past 30-days.
Wall Street analysts have assigned a consensus price target of 39 to the stock, which implies a rise of 68.51% to its current value. Analysts have been projecting 18 as a low price target for the stock while placing it at a high target of 60. It follows that stock’s current price would drop -46.58% in reaching the projected high whereas dropping to the targeted low would mean a loss of -46.58% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -22.30% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 2.18% while estimates for its earnings growth in next 5 years are of 3.85%.
Intellia Therapeutics Inc (NASDAQ:NTLA)’s Major holders
ARK INVESTMENT MANAGEMENT LLC is the top institutional holder at NTLA for having 11.6 million shares of worth $259.51 million. And as of 2024-06-30, it was holding 11.9575 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 9.6 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.0496 of outstanding shares, having a total worth of $214.79 million.
